These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis.
    Author: Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A.
    Journal: Chem Biol Interact; 2010 Mar 30; 184(3):423-30. PubMed ID: 20079348.
    Abstract:
    Colorectal cancer (CRC) is one of the most serious complications of inflammatory bowel disease. Tumor necrosis factor-alpha (Tnfalpha) is a major mediator of inflammation and there is increasing evidence that Tnfalpha/Tnf-receptor-1 (Tnfr1) signaling may act as an endogenous tumor promoter for colon carcinogenesis. In fact, a previous study revealed that mice lacking Tnfr1 develop significantly fewer colonic tumors in the inflammation-related CRC model. In addition, antibodies against Tnfalpha have been shown to inhibit the development of inflammation-related CRC. In the present study, Apc Min/+; Tnfalpha -/- mice were treated with 2% dextran sodium sulfate (DSS) and the tumor development was compared with Apc Min/+; Tnfalpha +/+ control mice in order to investigate the role of Tnfalpha by itself in the inflammation-related CRC. Surprisingly, there were no detectable differences in either the severity of colonic inflammation or the expression of DSS-induced chemokines and cytokines (Ccl2, Cxcl1, Tnfbeta, Il1beta, Il6, and Cox-2) that relate to the colonic inflammation and tumorigenesis between these two groups. Furthermore, the genetic ablation of Tnfalpha did not suppress the colon tumorigenesis in comparison to the wild-type mice. Our observations suggest that intricate inflammatory responses promote the inflammation-related mouse colon tumorigenesis.
    [Abstract] [Full Text] [Related] [New Search]